Navigation Links
Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that preliminary results from the ongoing data analysis of the recently-completed randomized, placebo-controlled, double-blind Phase III clinical trial of PROCHIEVE(R) 8% (progesterone gel) for the prevention of preterm birth in women with a previous preterm birth earlier than 35 weeks gestation has revealed a possible effect of PROCHIEVE 8% in delaying cervical shortening. A short cervix (equal to or less than 3.0 centimeters as measured by ultrasound in mid-pregnancy) is a known indicator of increased risk for preterm birth; as the rate of cervical shortening increases during pregnancy, the risk of a preterm birth increases.

Although an effect on cervical length was not the primary focus of this trial, per the study protocol cervical length measurements were performed on all women at baseline and at 28 weeks gestation. Data from the study show a delay in cervical shortening in patients treated with PROCHIEVE 8%, and suggest a correlation between the cervical length data, progesterone administration, and both a reduction in the likelihood of preterm birth and an improvement in infant outcomes.

"We are excited to share these unexpected findings, which may support the further development of PROCHIEVE 8% to prevent preterm birth in women with a short cervix. It is estimated that of the 4 million pregnancies each year in the United States, 10 to 30 percent of pregnant women have a cervical length of 2.5 to 3.0 centimeters, in mid-pregnancy. This includes many women with first-time pregnancies, the group that suffers the largest number of premature babies each year," said Robert S. Mills, president and chief executive officer of Columbia Laboratories. "We are planning to meet with the FDA in the coming months to explore the potential clinical and regulatory path for PROCHIEVE 8% to prevent preterm bir
'"/>




Page: 1 2 3

Related medicine technology :

1. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
2. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/ctd7zx/europe ) has announced the addition of ... (2014 - 2019)" report to their offering. ... Germany . This is followed by UK and ... Poland are the fastest growing segments. ... the basis of Product (Film Screen, Digital, 3D, Analog Systems, ...
(Date:6/2/2015)... Texas , June 2, 2015 ... report defines and segments the concerned market with ... valued at $261.8 million in 2014, and is ... a CAGR of 19.3% from 2014 to 2019. ... America Mannequin-Based Simulation Market for an analysis of ...
(Date:6/2/2015)... 2015 Intarcia Therapeutics, Inc. today ... its recently announced synthetic royalty / equity convert financing, ... have purchased Convertible Limited Recourse Notes from Intarcia and ... of any future global net sales of ITCA 650 ... also have the option, commencing upon U.S. regulatory approval ...
Breaking Medicine Technology:Europe Mammography Market Report 2014-2019 - Growth, Trends And Forecasts 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... results on Thursday, April 26, 2012, before the U.S. financial ... 8:30 AM EDT that day. Live audio ... link to the webcast may be accessed from the ,Events ...
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to ... DS Healthcare Limited to assist in introducing Clotamin to ... the agreement, DS Healthcare will evaluate the Clotamin formulation ...
Cached Medicine Technology:Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries 2
(Date:6/2/2015)... Erbelli’s Gourmet Pizzeria, Italian Bistro & ... handmade gourmet pizzas and calzones, fresh wraps, submarine sandwiches, ... new, the recipes are not—they have been satisfying the ... of the site is the menu, which is broken ... all the items. You can order directly from the ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 ZOOM+, the ... ZOOM+ Performance Health Insurance, announced today the opening of ... White 57 - a three-in-one complete dental exam, cleaning ... Jr. for kids. Like all ZOOM+ services, ZOOM+Smile can ... “Why shouldn’t the dentist office be as inviting as ...
(Date:6/2/2015)... June 02, 2015 Olive ... opening of Surrey’s first fertility clinic. Surrey ... a diverse, young community, with one of ... , Until now patients from Surrey ... to come into Vancouver or Burnaby for ...
(Date:6/2/2015)... TU-Automotive Detroit is the biggest dedicated B2B connected car ... execs from GM, Chrysler, Mercedes, Ford, TomTom, Zipcar, Nissan ... update on the automotive technology industry and a look ... secure one of the remaining passes. , Justin Parker, ... are 70 sessions looking across the connected car space ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Vancouver, ... by iData Research ( http://www.idataresearch.com ), the bone ... demineralized bone matrices (DBM) over traditional allograft materials. ... incisions and thus an increase in operation time, ... strong market growth in these synthetic materials is ...
Breaking Medicine News(10 mins):Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3
... 1 issue of the journal Sleep indicates that ... remain vigilant and attentive deteriorated significantly after losing less than ... study suggests that even moderate reductions in sleep duration can ... the academic performance of children with ADHD. Results of ...
... This release is also available in Chinese on ... Despite the absence of Medicare coverage, hospital use of computed ... the rise, according to a study in the March issue of ... www.jacr.org ). Colorectal cancer is the second leading cause of ...
... dissection, the current standard surgical treatment for localized non-small ... stage cases , according to a study published in the ... (JTO), the official journal of the International Association for the ... is very low in early-stage cancers with a maximum standard ...
... adhesive patches is at the center of an agreement ... arm of Italian pharmaceutical leader Zambon Co., SpA, to ... ways to deliver oral medications directly to a targeted ... sponsored research agreement between Zcube and UCSF, but is ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... fears soaring as quickly as a child,s rapidly rising temperature. ... Pediatrics (AAP) attempts to allay those fears by reminding parents ... against illness, and that lowering a fever may actually prolong ...
... , MONDAY, Feb. 28 (HealthDay News) -- Many American women ... treatment was tied to higher breast cancer risk. A sharp ... after. However, a new study suggests that the 2002-2003 ... continue through 2007. The data suggests that the drop ...
Cached Medicine News:Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 2Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 3Health News:Hospital use of virtual colonoscopy is on the rise, study suggests 2Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:UCSF collaborates with Zcube to develop new ways to deliver drugs 2Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Drop in Breast Cancer Among White Women May Have Stalled 2
... Vessel Dissector has application for use in ... the extraperitoneal spaces such as the retroperitoneal, ... be used in surgical procedures requiring dissection ... harvesting of a quality conduit through a ...
... The Thoratec VAD System includes three ... Drive Console or TLC-II Portable Driver. This ... when the natural heart, with conventional therapy, ... perfuse vital organs. To accomplish support, blood ...
... two distinct polyethylene glycol polymers that combine to ... to chemically bond to each other, as well ... material forms a flexible, watertight seal that remains ... withstand arterial pressure. It is completely resorbed by ...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
Medicine Products: